CYP-006TK Demonstrates Safety and Efficacy in DFU Clinical Trial
- Written by PR Newswire Asia - Asian Spectator
MELBOURNE, Australia, Dec. 5, 2024 /PRNewswire/ -- Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, has successfully completed its Phase 1 clinical trial of CYP-006TK in diabetic foot ulcers (DFU).
Key Highlights
- The trial met its primary objective, with...